Globus Medical is a medical device company focused on treating musculoskeletal disorders, primarily spine conditions. Globus sells implants — pedicle screw and rod systems, interbody fusion spacers, cervical plates, and biologics — directly to hospitals and ASCs on a per-surgery basis, with revenue driven by procedure volume, product mix, and average selling prices. The company goes to market through an exclusive sales force of direct employees and independent distributors who are present in the OR during most U.S. surgeries and maintain consigned implant inventory at hospitals. Globus supplements its core spine implant business with orthopedic trauma products, hip and knee arthroplasty systems, spinal cord stimulation (SCS) via the 2025 acquisition of Nevro, and intraoperative neuromonitoring services. Globus also sells an enabling technologies suite — including the ExcelsiusGPS robotic navigation system, intraoperative imaging, and augmented reality tools — which generates direct capital revenue and drives implant pull-through in installed accounts. Growth is driven by competitive rep recruiting, new product launches, and expanding the robotic installed base. The 2023 NuVasive merger roughly doubled Globus's scale, and integration — including in-sourcing NuVasive manufacturing into Globus's U.S. facilities — is a key near-term margin recovery driver. Manufacturing is predominantly U.S.-based, which limits tariff exposure. The company carries no debt and generates substantial free cash flow.